| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1370164 | Bioorganic & Medicinal Chemistry Letters | 2011 | 7 Pages |
Abstract
The optimization of a new series of muscarinic M3 antagonists is described, leading to the identification of AZD9164 which was progressed into the clinic for evaluation of its potential as a treatment for COPD.
Graphical abstractThe optimization of a new series of muscarinic M3 antagonists is described, leading to the identification of AZD9164, which was progressed into the clinic for evaluation of its potential as a treatment for COPD.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Antonio Mete, Keith Bowers, Eric Chevalier, David K. Donald, Helen Edwards, Katherine J. Escott, Rhonan Ford, Ken Grime, Ian Millichip, Barry Teobald, Vince Russell,